MedPath

Construction and Evaluation of China's Advanced Pancreatic Tumor Big Data Center

Conditions
Pancreatic Neoplasms
Registration Number
NCT05141656
Lead Sponsor
RenJi Hospital
Brief Summary

This study is a multi-center observational study. The start time for data collection is August 31, 2019. Patients who have been treated at our institution from August 31, 2019, who were diagnosed with pancreatic tumors on or before August 31, 2019 (diagnosed in our hospital or outside hospitals) would all meet the inclusion conditions of the study and be considered enrollment. Patients' baseline and treatment data will be collected under informed concent. The combination of medical big data governance and the leading technology of the big data platform uses real world data to improve the quality and efficiency of pancreatic tumor diagnosis, treatment and scientific research.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
20000
Inclusion Criteria
  1. Age ≥ 18, both male and female;
  2. Patients with primary pancreatic tumor diagnosed by histology, cytology or imaging;
  3. Clinical or pathological staging is locally advanced or metastatic pancreatic tumor (newly diagnosed or after surgery and other treatments);
  4. You can accept or have not received surgery, chemotherapy, radiotherapy, local treatment or traditional Chinese medicine for tumors;
  5. The subject voluntarily joined the study and signed an informed consent form voluntarily.
Exclusion Criteria
  1. Pancreatic tumors are evaluated as metastatic lesions, not primary tumors of the pancreas.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
OS5 years

overall survival

Secondary Outcome Measures
NameTimeMethod
DFS5 years

disease free survival

PFS5 years

progress free survival

Trial Locations

Locations (1)

RenJiH

🇨🇳

Shanghai, Shanghai, China

RenJiH
🇨🇳Shanghai, Shanghai, China

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.